Park J-H, Kang K-C, Shin D-E, Koh Y-G, Son J-S, Kim B-H
Department of Neurological Surgery, Yonsei Sarang Hospital, 478-3, Bangbae-dong, Seocho-gu, Seoul, Republic of Korea.
Osteoporos Int. 2014 Feb;25(2):613-8. doi: 10.1007/s00198-013-2458-7. Epub 2013 Aug 14.
The progression of fractured vertebral collapse is not rare after a conservative treatment of vertebral compression fracture (VCF). Teriparatide has been shown to directly stimulate bone formation and improve bone density, but there is a lack of evidence regarding its use in fracture management. Conservative treatment with short-term teriparatide is effective for decreasing the progression of fractured vertebral body collapse.
Few studies have reported on the prevention of collapsed vertebral body progression after osteoporotic VCF. Teriparatide rapidly enhances bone formation and increases bone strength. This study evaluated preventive effects of short-term teriparatide on the progression of vertebral body collapse after osteoporotic VCF.
Radiographs of 68 women with single-level osteoporotic VCF at thoracolumbar junction (T11-L2) were reviewed. Among them, 32 patients were treated conservatively with teriparatide (minimum 3 months) (group I), and 36 were treated with antiresorptive (group II). We measured kyphosis and wedge angle of the fractured vertebral body, and ratios of anterior, middle, and posterior heights of the collapsed body to posterior height of a normal upper vertebra were determined. The degree of collapse progression was compared between two groups.
The progression of fractured vertebral body collapse was shown in both groups, but the degree of progression was significantly lower in group I than in group II. At the last follow-up, mean increments of kyphosis and wedge angle were significantly lower in group I (4.0° ± 4.2° and 3.6° ± 3.6°) than in group II (6.8° ± 4.1° and 5.8° ± 3.5°) (p = 0.032 and p = 0.037). Decrement percentages of anterior and middle border height were significantly lower in group I (9.6 ± 10.3 and 7.4 ± 7.5 %) than in group II (18.1 ± 9.7 and 13.8 ± 12.2 %) (p = 0.001 and p = 0.025), but not in posterior height (p = 0.086).
In female patients with single-level osteoporotic VCF at the thoracolumbar junction, short-term teriparatide treatment did not prevent but did decrease the progression of fractured vertebral body collapse.
椎体压缩性骨折(VCF)保守治疗后,骨折椎体塌陷进展并不罕见。特立帕肽已被证明可直接刺激骨形成并提高骨密度,但缺乏其用于骨折治疗的证据。短期使用特立帕肽进行保守治疗对减少骨折椎体塌陷进展有效。
很少有研究报道骨质疏松性VCF后预防椎体塌陷进展的情况。特立帕肽能迅速增强骨形成并增加骨强度。本研究评估了短期特立帕肽对骨质疏松性VCF后椎体塌陷进展的预防作用。
回顾了68例胸腰段(T11-L2)单节段骨质疏松性VCF女性患者的X线片。其中,32例患者接受特立帕肽保守治疗(至少3个月)(第一组),36例接受抗吸收治疗(第二组)。我们测量了骨折椎体的后凸角和楔角,并确定了塌陷椎体的前、中、后高度与正常上位椎体后高度的比值。比较两组塌陷进展程度。
两组均出现骨折椎体塌陷进展,但第一组的进展程度明显低于第二组。在最后一次随访时,第一组后凸角和楔角的平均增加量(4.0°±4.2°和3.6°±3.6°)明显低于第二组(6.8°±4.1°和5.8°±3.5°)(p = 0.032和p = 0.037)。第一组前、中边界高度的减少百分比(9.6±10.3和7.4±7.5%)明显低于第二组(18.1±9.7和13.8±12.2%)(p = 0.001和p = 0.025),但后高度无明显差异(p = 0.086)。
在胸腰段单节段骨质疏松性VCF的女性患者中,短期特立帕肽治疗不能预防但可减少骨折椎体塌陷进展。